No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
IDXX IDEXX Laboratories Inc
- 475.670
- -2.120-0.44%
Trading Apr 19 12:08 ET
39.51BMarket Cap47.28P/E (TTM)
482.210High473.620Low145.24KVolume482.200Open477.790Pre Close69.20MTurnover0.18%Turnover Ratio47.28P/E (Static)83.05MShares583.39052wk High26.61P/B39.08BFloat Cap372.50052wk Low--Dividend TTM82.15MShs Float706.950Historical High--Div YieldTTM1.80%Amplitude2.313Historical Low476.456Avg Price1Lot Size
Intraday
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Top 10 Most Oversold S&P 500 Stocks
TMO Vs. IDXX: Which Stock Is the Better Value Option?
$1000 Invested In IDEXX Laboratories 10 Years Ago Would Be Worth This Much Today
IDEXX Laboratories (NASDAQ:IDXX) has outperformed the market over the past 10 years by 13.2% on an annualized basis producing an average annual return of 23.57%. Currently, IDEXX Laboratories has a ma
IDEXX Laboratories, Inc. (NASDAQ:IDXX) Investors Are Less Pessimistic Than Expected
IDEXX Laboratories, Inc.'s (NASDAQ:IDXX) price-to-earnings (or "P/E") ratio of 48.9x might make it look like a strong sell right now compared to the market in the United States, where around half of t
First Mixed-use Building at The Downs Will Add Housing Near Costco, Idexx
IDEXX Laboratories to Release 2024 First Quarter Financial Results
IDEXX Laboratories, Inc. (NASDAQ:IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2024 first quarter results for Wednesday, May 1, 2024, before the market opens. The Company will
Comments
$IDEXX Laboratories Inc(IDXX.US$ 👀 Here's How Much You Would Have Made Owning
IDEXX Laboratories Stock In The Last 15 Years!
IDEXX Laboratories Stock In The Last 15 Years!
The share price seems to largely reflect the EPS growth, indicating that investor sentiment towards the shares hasn't changed significantly. The company's consistent positive reception from the market suggests it may be worth watching for potential investment.
IDEXX Laboratories' high P/E ratio, inferior earnings outlook, and slower market growth could lead to a share price decline. This high P/E ratio may not be sustainable, posing a risk to shareholders and potential investors.
Long-term performance of IDEXX shows positive returns despite recent downturn. Market caution and strong momentum warrant closer scrutiny. Nonetheless, investors should note the existent 2 warning signs.
ColumnsAnimal Health Q2 Preview_JP Morgan
Comment:
Animal health companies ELAN, ZTS and IDXX are expecting a relatively uneventful Q2 following a turbulent Q1. For ZTS, the company is expected to see more normalized results for its companion business after distributor destocking in Q1. The company's new product cycle is forecasted to offset any macro challenges in Europe, and it remains the favorite AH name into the Librela US launch. Meanwhile, IDXX is expected to have an uneventful quarter with healt...
Animal health companies ELAN, ZTS and IDXX are expecting a relatively uneventful Q2 following a turbulent Q1. For ZTS, the company is expected to see more normalized results for its companion business after distributor destocking in Q1. The company's new product cycle is forecasted to offset any macro challenges in Europe, and it remains the favorite AH name into the Librela US launch. Meanwhile, IDXX is expected to have an uneventful quarter with healt...
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg